Ascendis Pharma ( (ASND) ) has provided an announcement.
On March 11, 2025, Ascendis Pharma’s board of directors granted 35,520 warrants to certain employees, allowing them to subscribe for ordinary shares at an exercise price of $145.63 per share. This move is part of the company’s strategy to incentivize employees and aligns with its Articles of Association. The warrants will vest over a period, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to continued service. This grant leaves 1,911,453 shares available for future warrant issuance, potentially impacting the company’s capital structure and employee retention strategies.
More about Ascendis Pharma
Ascendis Pharma A/S is a Danish company focused on developing medical preparations to combat diseases. The company is involved in manufacturing and selling these preparations and holds shares in companies with similar objectives.
YTD Price Performance: 5.53%
Average Trading Volume: 465,255
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $8.72B
Learn more about ASND stock on TipRanks’ Stock Analysis page.